Edition:
United Kingdom

Lantheus Holdings Inc (LNTH.OQ)

LNTH.OQ on NASDAQ Stock Exchange Global Market

21.93USD
23 Aug 2019
Change (% chg)

$-0.86 (-3.77%)
Prev Close
$22.79
Open
$22.79
Day's High
$22.99
Day's Low
$21.82
Volume
116,843
Avg. Vol
138,714
52-wk High
$29.80
52-wk Low
$12.60

Latest Key Developments (Source: Significant Developments)

Lantheus Holdings' Unit Refinanced Its Existing Indebtedness With New Term Loan Facility
Monday, 1 Jul 2019 

July 1 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS INC - ON JUNE 27, CO'S UNIT REFINANCED ITS EXISTING INDEBTEDNESS WITH NEW TERM LOAN FACILITY AND A NEW REVOLVING CREDIT FACILITY.LANTHEUS HOLDINGS INC - CREDIT AGREEMENT REPLACES THE OLD TERM FACILITY WITH A NEW FIVE-YEAR $200.0 MILLION TERM LOAN FACILITY.LANTHEUS HOLDINGS INC - CREDIT AGREEMENT REPLACES THE OLD REVOLVING FACILITY WITH A NEW $200.0 MILLION FIVE-YEAR REVOLVING CREDIT FACILITY.  Full Article

Lantheus Announces Strategic Collaboration With Nanomab
Thursday, 30 May 2019 

May 30 (Reuters) - Lantheus Holdings Inc ::LANTHEUS ANNOUNCES STRATEGIC COLLABORATION WITH NANOMAB TO PROVIDE A NOVEL BIOMARKER FOR CLINICAL DEVELOPMENT AND MANAGEMENT OF IMMUNO-ONCOLOGY THERAPIES.LANTHEUS HOLDINGS INC - UNDER COLLABORATION AGREEMENT, LANTHEUS WILL LICENSE NANOMAB'S NM-01.LANTHEUS HOLDINGS INC - NANOMAB PLANS TO FILE AN INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER IN UNITED KINGDOM IN SECOND HALF OF 2019 FOR NM-01.  Full Article

Lantheus Holdings Q1 GAAP Earnings Per Share $0.25
Tuesday, 30 Apr 2019 

Lantheus Holdings Inc ::LANTHEUS HOLDINGS, INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.28.Q1 GAAP EARNINGS PER SHARE $0.25.Q1 REVENUE $86.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $86.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.25 -- REFINITIV IBES DATA.SEES Q2 FY 2019 REVENUE GROWTH 0.5% - 5.2%.SEES Q2 REVENUE $86 MILLION - $90 MILLION.SEES Q2 ADJUSTED DILUTED EPS $0.23 - $0.28.SEES FY 2019 REVENUE GROWTH 4.25% - 5.75%.SEES FY 2019 REVENUE $358 MILLION - $363 MILLION.SEES FY 2019 ADJUSTED DILUTED EPS $1.14 - $1.17.FY2019 EARNINGS PER SHARE VIEW $1.16, REVENUE VIEW $360.8 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.30, REVENUE VIEW $90.6 MILLION -- REFINITIV IBES DATA.  Full Article

Lantheus Holdings Sees 2019 Adjusted Diluted EPS $1.14 - $1.17
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 REVENUE $86.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $83.7 MILLION.SEES 2019 ADJUSTED DILUTED EPS $1.14 - $1.17.SEES FY 2019 REVENUE $358 MILLION - $363 MILLION.SEES Q1 FY 2019 ADJUSTED DILUTED EPS $0.23 - $0.25.SEES Q1 2019 REVENUE $85 MILLION - $87.5 MILLION.FY2019 EARNINGS PER SHARE VIEW $0.96, REVENUE VIEW $361.5 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.24, REVENUE VIEW $88.5 MILLION -- REFINITIV IBES DATA.  Full Article

Lantheus Holdings Q3 Earnings Per Share $0.24
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS, INC. REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.24.SEES FY 2018 REVENUE $337 MILLION TO $342 MILLION.Q3 REVENUE $88.9 MILLION VERSUS I/B/E/S VIEW $83.3 MILLION.Q3 EARNINGS PER SHARE VIEW $0.18 -- THOMSON REUTERS I/B/E/S.COMPANY REAFFIRMS FULL-YEAR REVENUE AND UPDATES ADJUSTED EBITDA GUIDANCE.SEES 2018 GUIDANCE RANGE FOR ADJUSTED EBITDA $90 MILLION TO $93 MILLION.  Full Article

GE Healthcare, Lantheus Starts A Phase 3 Clinical Trial Of Flurpiridaz
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Lantheus Holdings Inc ::GE HEALTHCARE AND LANTHEUS ANNOUNCE START OF A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ, AN INVESTIGATIONAL AGENT BEING EVALUATED FOR THE DETECTION OF CORONARY ARTERY DISEASE.GE HEALTHCARE AND LANTHEUS ANNOUNCE START OF A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ, AN INVESTIGATIONAL AGENT BEING EVALUATED FOR THE DETECTION OF CORONARY ARTERY DISEASE.  Full Article

Lantheus Says NTP Radioisotopes Instituted Temporary Suspension Of Production Operations At Facility In South Africa
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS - NTP RADIOISOTOPES INSTITUTED TEMPORARY SUSPENSION OF PRODUCTION OPERATIONS AT MOLYBDENUM-99 PROCESSING FACILITY IN SOUTH AFRICA.LANTHEUS HOLDINGS - NTP'S RESUMPTION OF OPERATIONS WILL DEPEND ON APPROVAL BY SOUTH AFRICAN NUCLEAR REGULATOR OF NTP'S REMEDIATION EFFORTS.LANTHEUS HOLDINGS INC SAYS UNIT RECEIVED NOTICE FROM NTP RADIOISOTOPES (SOC) LTD - SEC FILING.LANTHEUS HOLDINGS INC - MANAGEMENT IS NOT CHANGING ITS FINANCIAL GUIDANCE AT THIS TIME.LANTHEUS HOLDINGS - WILL WORK TO SOURCE ADDITIONAL MO-99 FROM OTHER SUPPLIERS DURING NTP'S CURRENT SUSPENSION OF OPERATIONS.  Full Article

Lantheus Holdings Reports Q4 Earnings Per Share $2.47
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS, INC. REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE.Q4 EARNINGS PER SHARE $2.47.SEES FY 2018 REVENUE ABOUT $337 MILLION TO $342 MILLION.SEES Q1 2018 REVENUE $78 MILLION TO $83 MILLION.Q4 REVENUE ROSE 9.3 PERCENT TO $81.2 MILLION.‍Q4 2017 WORLDWIDE REVENUES OF $81.2 MILLION, A 9.3% INCREASE OVER PRIOR YEAR PERIOD​.  Full Article

Lantheus Holdings Says Lantheus Medical Entered Extension Of Supply Agreement With Jubilant Drax Images​
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Lantheus Holdings Inc ::LANTHEUS HOLDINGS-ON DEC. 30, 2017, LANTHEUS MEDICAL ENTERED BINDING EXTENSION OF SUPPLY AGREEMENT WITH JUBILANT DRAX IMAGES,EFFECTIVE JAN. 1, 2018 ​.LANTHEUS HOLDINGS INC - ‍LMI WILL CONTINUE TO SUPPLY TRIAD WITH TECHNELITE GENERATORS, XENON, NEUROLITE AND OTHER PRODUCTS THROUGH 2020 - SEC FILING​.LANTHEUS HOLDINGS INC - ‍EXTENDED SUPPLY AGREEMENT WILL EXPIRE ON DECEMBER 31, 2020​.  Full Article

Lantheus Holdings reports Q3 earnings per share $0.22
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Lantheus Holdings Inc :Lantheus Holdings Inc reports 2017 third quarter financial results; exceeds third quarter and raises full-year 2017 guidance.Q3 earnings per share $0.22.Q3 revenue $79.9 million versus I/B/E/S view $77.3 million.Sees fy 2017 revenue $323 million to $325 million.Q3 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Lantheus Holdings Inc - ‍increased its full-year 2017 guidance range for adjusted EBITDA to $86 million to $88 million from previous guidance of $82 million to $85 million​.Lantheus Holdings Inc - fy guidance for both revenue and adjusted EBITDA excludes impact of a $5.0 million up-front payment received in q2 of 2017 from GE Healthcare​.  Full Article